OOIR: Observatory of International Research

Papers

(The H4-Index of Hepatology Communications is 35. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Single‐Cell, Single‐Nucleus, and Spatial RNA Sequencing of the Human Liver Identifies Cholangiocyte and Mesenchymal Heterogeneity	93
Prevalence and Profile of Nonalcoholic Fatty Liver Disease in Lean Adults: Systematic Review and Meta‐Analysis	88
Hepatocellular Carcinoma Survival by Etiology: A SEER‐Medicare Database Analysis	82
Effects of Resmetirom on Noninvasive Endpoints in a 36‐Week Phase 2 Active Treatment Extension Study in Patients With NASH	81
Inverse Association of Telomere Length With Liver Disease and Mortality in the US Population	81
Role of Cholesterol‐Associated Steatohepatitis in the Development of NASH	75
Donor Fecal Microbiota Transplantation Alters Gut Microbiota and Metabolites in Obese Individuals With Steatohepatitis	70
Nonalcoholic Fatty Liver Disease Increases the Risk of Anxiety and Depression	69
Hepatocellular Carcinoma–Circulating Tumor Cells Expressing PD‐L1 Are Prognostic and Potentially Associated With Response to Checkpoint Inhibitors	58
Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD	58
Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139‐Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection	58
Mortality of NAFLD According to the Body Composition and Presence of Metabolic Abnormalities	56
Clinical Features of Patients With COVID‐19 With Nonalcoholic Fatty Liver Disease	55
The Value of Liver and Spleen Stiffness for Evaluation of Portal Hypertension in Compensated Cirrhosis	55
Characterization and Proteome of Circulating Extracellular Vesicles as Potential Biomarkers for NASH	52
Poor Awareness of Liver Disease Among Adults With NAFLD in the United States	51
Coronavirus Disease 2019 in Autoimmune Hepatitis: A Lesson From Immunosuppressed Patients	51
The Growing Burden of Disability Related to Nonalcoholic Fatty Liver Disease: Data From the Global Burden of Disease 2007‐2017	50
TM6SF2: A Novel Genetic Player in Nonalcoholic Fatty Liver and Cardiovascular Disease	48
Hepatic Stellate Cell Regulation of Liver Regeneration and Repair	48
Nonalcoholic Fatty Liver Disease and Alcoholic Liver Disease are Major Drivers of Liver Mortality in the United States	48
Drug‐Induced Liver Injury in GI Practice	47
Human Nonalcoholic Steatohepatitis on a Chip	42
Covid‐19 and Liver Injury: Role of Inflammatory Endotheliopathy, Platelet Dysfunction, and Thrombosis	41
Fecal Microbiota Transplant in Cirrhosis Reduces Gut Microbial Antibiotic Resistance Genes: Analysis of Two Trials	41

Alcohol‐Associated Liver Disease Before and After COVID‐19—An Overview and Call for Ongoing Investigation	40
Nonalcoholic Fatty Liver Disease Screening in Type 2 Diabetes Mellitus Patients in the Primary Care Setting	39
Liver Care and Surveillance: The Global Impact of the COVID‐19 Pandemic	39
SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASH	38
Impact of COVID‐19 in Liver Disease Progression	37
A multi‐analyte cell‐free DNA–based blood test for early detection of hepatocellular carcinoma	37
Nonalcoholic Fatty Liver Disease Prevalence Trends Among Adolescents and Young Adults in the United States, 2007‐2016	36
Aspirin Use Is Associated with a Reduced Incidence of Hepatocellular Carcinoma: A Systematic Review and Meta‐analysis	36
Liver Injury in Patients Hospitalized with Coronavirus Disease 2019 Correlates with Hyperinflammatory Response and Elevated Interleukin‐6	36
Exosome‐Like Nanoparticles From Lactobacillus rhamnosus GG Protect Against Alcohol‐Associated Liver Disease Through Intestinal Aryl Hydrocarbon Receptor in Mice	35
Liver Fibrosis Index FIB‐4 Is Associated With Mortality in COVID‐19	35
Definition of Healthy Ranges for Alanine Aminotransferase Levels: A 2021 Update	35